Category: Recent News
Shelley J. Russek, PhD, professor of pharmacology at Boston University School of Medicine (BUSM), and director of the School’s Graduate Program for Neuroscience, was recently honored with an award from the CURE (Citizens United for Research in Epilepsy) Foundation. The prestigious award, given as well to her colleague Amy Brooks-Kayal, MD, from University of Colorado Denver, will fund research studies for new drugs for epilepsy treatment.
Approximately 65 million people worldwide have epilepsy. Although certain brain injuries are known to predispose someone to epilepsy, there are no treatments that reduce this risk. Russek and her colleagues have found that an important cellular signaling pathway, the JAK/STAT pathway, is activated after brain injuries that lead to epilepsy, and that inhibiting this activation reduces subsequent seizure frequency in an experimental model. “We expect to identify lead JAK/STAT inhibitors that can be advanced towards clinical testing to prevent or inhibit development of acquired epilepsy following brain injury,” explained Russek.
CURE was founded by parents of children with epilepsy who were frustrated with their inability to protect their children from the devastation of seizures and the side effects of medications. Unwilling to sit back and accept the debilitating effects of epilepsy, these parents joined forces to spearhead the search for a cure. Each year, grants are funded based on promising trends in the field and the potential for breakthroughs in a specified area. Russek was selected with the assistance of the CURE Scientific Advisory Board, the Lay Review Council, and the scientific peer reviewers who generously volunteer their time to CURE.
CURE has raised more than $26 million to fund research and other initiatives. CURE funds seed grants to young and established investigators to explore new areas and collect the data necessary to apply for further funding by the National Institutes of Health. To date, CURE has awarded 151 cutting-edge projects.
Originally posted on the Boston University Medical Campus website.
The Peter F. McManus Charitable Trust Foundation recently honored Dr. Valentina Sabino for the second time with a grant to research the causes of alcohol addiction. The title of her approved project is “Neurobiological Bases of Alcohol Addiction.”
According to Dr. Sabino, “alcoholism constitutes one of the most serious public health problems worldwide. The World Health Organization estimates that about 2 billion people worldwide consume alcoholic beverages, of which 76.3 million have alcohol use disorders. Alcohol is estimated to cause 20%–30% of esophageal cancer, liver cancer and cirrhosis, homicide, seizures, and motor vehicle accidents, causing 3.2% of the total deaths.
This project will systematically explore the role of an understudied receptor system, the Sigma receptors, in genetic and chronic ethanol-induced animal models of alcoholism. The focus will be the Nucleus Accumbens, an important brain region for alcohol and drug addiction, proposed as being the specific region where Sigma receptors mediated neuroplasticity in addicted brains.
These experiments will provide insights into this novel receptor system as a key mechanism involved in excessive drinking and alcohol-seeking behavior and propose a novel therapeutic target for alcohol addiction.”
Dr. Sabino received her Ph.D. in Pharmacology in 2006. She is an Assistant Professor in the Department of Pharmacology & Experimental Therapeutics and Department of Psychiatry, and Co-Director of the Laboratory of Addictive Disorders at Boston University School of Medicine.
Congratulations, Dr. Sabino!
Dr. Camron Bryant has been selected as the recipient of the 2014 IBANGS Young Scientist Award. The Young Scientist Award honors a scientist who is 7 or fewer years post first faculty or faculty-equivalent appointment, and whose area of research is in behavioural and neural genetics. Key considerations are the scientific importance of research discoveries, record of achievement and future scientific plans and projected impact on the field.
Congratulations, Dr. Bryant!
I am pleased to share that Benjamin Wolozin, MD, PhD, Professor, Pharmacology and Neurology, was awarded the Alzheimer’s Association Zenith Fellows Award. Initiated in 1991, the award provides support for cutting edge basic science or biomedical research that addresses fundamental problems related to early detection, etiology pathogenesis, treatment and/or prevention of Alzheimer’s disease (AD). The award is valued at $450,000, which will be dispersed over three years.
The Wolozin Lab won the award with its proposal “It Takes TIA to Tangle: The Role of RNA Binding Proteins in AD.” The laboratory already has discovered a RNA binding protein that induces tau misfolding, one of the essential steps that leads to cognitive loss in AD. This award will allow the Wolozin Lab to experimentally induce the misfolding, investigate the factors that regulate the misfolding and in the future, potentially design therapeutics to prevent the misfolding.
Please join me in congratulating Dr. Wolozin on this award.Karen Antman, MD Provost, Boston University Medical Campus Dean, School of Medicine Professor of Medicine
Kenneth J. Rhodes, Ph.D., Vice President of Neurology Discovery at Biogen Idec and an alumni of the Boston University Pharmacology Training Program, led the team of researchers that developed Tecfidera, an oral medication that defends against relapsing Multiple Sclerosis (MS).
The Food and Drug Administration recently approved Tecfidera, also known as dimethyl fumarate, for treating relapsing multiple sclerosis. This new drug delays progression of physical disability and slows the development of brain lesions associated with MS. It also reduces the inflammation caused when the immune system attacks myelin, which ultimately results in less damage to myelin in the body. In a Biogen Idec press release, Dr. Kenneth Rhodes stated that, “these exciting results support further research, as the data suggest that neublastin may have the potential to promote sensory neuronal regeneration and functional recovery following injury. The neublastin program is part of Biogen Idec’s commitment to innovative neurological science and discovery.”
According to the Boston Business Journal, Tecfidera “tops the list of the biggest potential revenue-generating drugs launched so far this year in the U.S., with expected sales of $2.9 billion by 2018.”
Dr. Kenneth Rhodes joined Biogen Idec in May 2007 after spending ten years in the Neuroscience Department at Wyeth, where he also led neurodegeneration drug discovery teams researching MS among epilepsy, stroke, Parkinson’s and Alzheimer’s disease. He served as a postdoctoral trainee under the mentorship of Dr. David H. Farb, Professor and Chair of Pharmacology at Boston University School of Medicine, from 1992-1993. Dr. Rhodes has published over 50 research papers in peer-reviewed journals such as Nature, Neuron, and the Journal of Neuroscience and most recently was the Keynote Speaker for the 2013 BU-Pfizer Symposium on “Therapeutic Innovation: Oxidative Stress and the Next Generation of Discovery” held November 5, 2013.
The September 2013 issue of The Pharmacologist is now available online. Read about new Executive Officer Judith A. Siuciak, some thoughts from President Rick Neubig, the program for the Joint ASPET/Chinese Pharmacological Society Annual Meeting at Experimental Biology 2014, and more. Be sure to check it out!
|In this issue:
Originally published by the American Society for Pharmacology and Experimental Therapeutics
Dr. Wendy Wei Qiao Qiu was chosen to receive the 2013 Johnson & Johnson Clinical Innovation Award Program (J&J CIAP) award. According to the BU Institute for Technology Entrepreneurship & Commercialization website, the J&J CIAP was designed to “stimulate innovative solutions to unmet clinical challenges emerging from the Boston University medical community” by funding research projects with the greatest potential to impact human health.
Dr. Qiu was chosen for this recognition from many talented Boston University practicing clinicians for her research on Alzheimer’s disease. As an awardee of the Clinical Innovation Award Program, she will be recognized at the program’s annual event, invited to serve as clinical advisor to the project team, and will have an opportunity to contribute to breakthrough medical technologies. In addition, she will be supported with an initial development grant of up to $15,000.
An Associate Professor of Psychiatry and Pharmacology, Dr. Qiu is the Principal Investigator in the Laboratory of Molecular Psychiatry in Aging in the Department of Pharmacology & Experimental Therapeutics.
Congratulations, Dr. Qiu!
Hui Feng spends a lot of time staring through zebra fish. Through because these vertebrates, which have a great deal of genetics in common with humans, are transparent. In fact, one particular breed, called Casper—after the Friendly Ghost—is so phantasmal that Feng says that “you can read newspapers through this fish.”
Feng doesn’t read the news through them, though. The School of Medicine assistant professor of pharmacology and medicine is more interested in tracking the pathways of dyed tumor cells as they metastasize through the zebra fish’s vasculature, which is tinted a contrasting color. In the less than two years since her tank-filled lab opened, she has identified genes that, when blocked with targeted treatments, could prevent the metastasis of certain types of cancer, like the most stubborn forms of leukemia.
In recognition of her groundbreaking work, Feng was awarded the Ralph Edwards Career Development Professorship, which recognizes MED researchers. The award was made possible this year by the estate of obstetrician and gynecologist Ralph Edwards (MED’52).
Feng, director of the Laboratory of Zebrafish Genetics & Cancer Therapeutics, says the honor reminds her that University officials appreciate faculty research and they want to support it. “It’s not just about the money,” she says. “The spiritual or mental support really means so much to us.”
Karen Antman, MED dean and Medical Campus provost, recalls the researcher’s discoveries early in her career, which found their way to top-tier research journals, including Nature, Cell Biology, Cancer Cell, the Journal of Experimental Medicine, and PNAS. A graduate of Beijing Medical University, Feng completed a master’s in cardiovascular pharmacology at Peking Union Medical College and a doctorate in cellular biology at the University of Georgia.
“Since joining the School of Medicine faculty,” Antman says, “Dr. Feng has demonstrated an exceptional level of scholarship, mentorship, teaching, and collegiality and quickly established herself as an independent research scientist, effectively and efficiently setting up a robust research program.”
Feng is one of three assistant professors who were given career development awards, which recognize junior faculty who have been at the University for less than two years and have held no prior professorships. Cornel Ban, a College of Arts & Sciences assistant professor of international relations, received the inaugural Stuart and Elizabeth Pratt Career Development Professorship, dedicated to CAS scholars. And Nachiketa Sahoo, a School of Management assistant professor of information systems, was awarded the Reidy Family Career Development Professorship, which has recognized faculty members in SMG and the College of Engineering in alternating years since 2010.
Contributions from BU trustee Stuart W. Pratt (CAS’69) and his wife, Elizabeth, and trustee Richard D. Reidy (SMG’82) and his wife, Minda G. Reidy (SMG’82, GSM’84) made the professorships possible.
Each award comes with a three-year nonrenewable stipend used to support scholarly or creative work and to cover a portion of the faculty member’s salary. Deans of the respective schools or colleges nominate faculty for these honors, and the Office of the Provost makes the final selections.
“We are extremely grateful to Stuart and Elizabeth Pratt, Richard and Minda Reidy, and posthumously, Ralph Edwards for their generosity and for the vision they’ve shown in supporting the future of these very important fields,” says Jean Morrison, University provost and chief academic officer. These three professors were recognized for “their extraordinary accomplishments in areas of study, passion for the creation and transmission of knowledge, and their efforts to enhance the student experience.”
Ban’s research has focused on economic issues in Brazil, Spain, and Romania, and spans three principal topics: international finance, international economic organizations, and the diffusion of international economic ideas. He describes his first book, Governing Crises: The International Politics of Crisis Economics from Bretton Woods to the Great Recession, not yet published, as “a cautionary tale about how much we don’t know about how the financial markets work.” He is an expert on the failure of economic models used by governments or international banks to predict the financial crisis that swept the world within the past decade.
Ban earned a bachelor’s from Babes-Bolyai University, in Romania, a master’s degree from the University of Delaware, and a doctorate in political science from the University of Maryland. He says the award will give him the time and funding to launch his next book project, which will focus on the dynamics of international finance over the past couple of decades. “Without this kind of support,” he says, “I could not get it done.”
Andrew Bacevich, a CAS professor of history and international relations and acting chair of international relations, calls Ban an “emerging superstar” in the department. “Since his arrival a year ago, he has become a valued asset,” he says. “His performance as a teacher and scholar has demonstrated that he is precisely the sort of young faculty member for whom the Stuart and Elizabeth Pratt Career Development Professorship is designed.”
Sahoo holds a master’s degree in knowledge discovery and data mining and a doctorate in information systems and management, both from Carnegie Mellon University. His current research focus is on improving personalized information filtering techniques, such as that used by Netflix and Amazon, to help customers find products that best match their past interests. Recognizing that people are dynamic and that their preferences change over time, he has adjusted these filtering techniques so that they show more accurate recommendations across a variety of platforms.
In a separate branch of research, Sahoo is analyzing the messages exchanged between individuals on corporate social media, such as blogs, to identify expertise that exists inside a company.
“New technologies to help people connect to each other are exacerbating the problem of information overload at a personal level,” says Sahoo. “There is too much information to sift through and there is limited time. It’s important to develop tools and techniques that help us find the bits of relevant information faster.”
Sahoo says he will use the award to hire a research assistant to help with data collection and analysis.
“Dr. Sahoo is a wonderful addition to our faculty: a productive researcher, a great colleague, and a committed teacher,” says Kenneth Freeman, SMG’s Allen Questrom Professor and Dean.
The Alzheimer’s Art Quilt Initiative (AAQI) honored Dr. Tsuneya Ikezu, Professor of Pharmacology and Neurology, last week for his continued efforts in Alzheimer’s disease research. AAQI is a national grassroots charity that raises awareness and funds research through the donation and sale of small art quilts.
Marge Farquharson and Dawn Forde, AAQI representatives, visited the Department of Pharmacology & Experimental Therapeutics at Boston University School of Medicine to present a quilt to Dr. Ikezu and the Laboratory of Molecular NeuroTherapeutics. This particular quilt displays 54 names of those afflicted by Alzheimer’s disease on the dull side of the fabric to symbolize the mental fading that occurs in 5.4 million patients in the nation and their loss of memories and skills. Each name represents the story of a once vital and productive individual.
Dr. Ikezu also received $60,560 for future AD research projects. His earlier study, “Exosome-mediated dissemination of tau aggregation in Alzheimer’s,” investigated the role of microglia in mediating the spread of tau aggregation. Hopefully this study will provide a new therapeutic target for the treatment of Alzheimer’s disease.
The Alzheimer’s Art Quilt Initiative is an all-volunteer organization that has raised more than $925,000 for Alzheimer’s disease research since January 2006. AAQI’s goal is to raise $1,000,000 by the end of 2013 and to provide funding directly to Alzheimer’s disease researchers. In this way AAQI aims to make a difference, one quilt at a time! For more information on the Alzheimer’s Art Quilt Initiative, please click here.
Congratulations on your award and recognition, Dr. Ikezu!
Rachel L. Flynn, Ph.D., Assistant Professor in the Departments of Pharmacology & Experimental Therapeutics and Medicine, Section of Hematology and Medical Oncology, and a member of The Cancer Center, was awarded a $50,000 grant for the coming year from the FOSTER (Fighting Osteosarcoma Through Everyday Research) Foundation. Dr. Flynn was recruited to BU from the Massachusetts General Cancer Center in June 2013. This is the first funding award for which Rachel has applied since joining the BUSM faculty in June.
FOSTER Foundation was established in June 2001 by Stacey Leondis, then a student at Garden City High School, to support osteosarcoma research. Osteosarcoma is a rare form of bone cancer primarily affecting children.
Kudos to Dr. Flynn and welcome to BUSM!